Organization | Hangzhou Seventh People's Hospital

Hangzhou Seventh People's Hospital Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2017

NCT03219008

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Hangzhou Seventh People's Hospital

Active Ingredients

Drugs in Phase 4 Trials (5)

amfebutamone (1 trial)

fluoxetine (prozac) (1 trial)

fluvoxamine (luvox) (2 trials)

lithium (lithonate) (1 trial)

mirtazapine (remeron) (1 trial)

Drugs in Phase 2 Trials (4)

aripiprazole (abilify) (1 trial)

memantine (namenda) (1 trial)

sertraline (zoloft) (1 trial)

venlafaxine (effexor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Compulsive Personality Disorder (Phase 2)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Disease (Phase 4)

Obsessive-Compulsive Disorder (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 2
# of Trial APIs: 9